Research Article
Radiomic Features of 18F-FDG PET in Hodgkin Lymphoma Are Predictive of Outcomes
Table 2
Characteristics of the training and validation cohorts.
| | Total (n = 65) | Training (n = 49) | Validation (n = 16) | |
| Sex | | | | 0.596 | Male | 45 (69.2%) | 34 (69.4%) | 11 (68.8%) | Female | 20 (30.8%) | 15 (30.6%) | 5 (31.3%) |
| Age, median (range) | 29.0 (8–72) | 29 (8–72) | 30 (16–54) | 0.703 |
| Ann Arbor stage | | | | 0.585 | I-II | 36 (55.4%) | 27 (55.1%) | 9 (56.3%) | III-IV | 29 (44.6%) | 22 (44.9%) | 7 (43.8%) |
| Bulky disease | | | | 0.678 | >10 cm | 9 (13.8%) | 6 (12.2%) | 3 (18.8%) | <10 cm | 56 (86.2%) | 43 (87.8%) | 13 (81.3%) |
| BM | | | | 0.612 | Yes | 9 (13.8%) | 7 (14.3%) | 2 (12.5%) | No | 56 (86.2%) | 42 (85.7%) | 14 (87.5%) |
| Extranodal sites | | | | 0.495 | Yes | 25 (38.5%) | 20 (40.8%) | 5 (31.3%) | No | 40 (61.5%) | 29 (59.2%) | 11 (68.8%) |
| B symptoms | | | | 0.389 | Yes | 22 (33.8%) | 18 (36.7%) | 4 (25.0%) | No | 43 (66.2%) | 31 (63.3%) | 12 (75.0%) |
| Chemotherapy with IFRT | | | | 0.565 | Yes | 4 (6.2%) | 4 (8.2%) | 0 (0.0%) | No | 61 (93.8%) | 45 (91.8%) | 16 (100.0%) |
|
|
LDH, lactate dehydrogenase, BM, bone marrow; IFRT, involved-field radiation therapy.
|